• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconEli Lilly

Eli Lilly

Page 3 of 7
NewslettersIn this year’s Global 500 list: Energy woes, retail gains, and boom times for AI and weight-loss drugs
By Lydia BelangerAugust 5, 2024
MagazineHow Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut
By Erika FryAugust 2, 2024
Thomas Schinecker, chief executive officer of Roche
FinanceSwiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss
By Prarthana PrakashJuly 29, 2024
A bathroom scale is surrounded by colorful pills.
HealthPharma giant Pfizer is trying to cash in on the weight loss drug craze with a new pill that could be a welcome needle-free alternative to pesky GLP-1 shots
By Damian Garde and BloombergJuly 11, 2024
A person using Ozempic on November 2, 2023, in Madrid, Spain. Novo Nordisk, the Danish firm that manufactures Ozempic, has reported record quarterly results, up almost 3% on the stock market. The company's revenues rose by 38% to DKK 58.73 billion, some 7.8 billion euros. Ozempic is a diabetic drug that causes a loss of up to 15% of body weight because it acts as an appetite suppressant, a side effect that has made the drug fashionable on social media as a weight loss drug.
FeaturesOzempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree
By Jessica Mathews and Alena BotrosJuly 9, 2024
CommentaryAlzheimer’s made my mom unable to recognize her grandkids. Breakthroughs too late for her can change the disease’s trajectory—if diagnosis and treatment start early
By Anne E. WhiteJuly 2, 2024
HealthFake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
By Amanda LoudinJune 27, 2024
HealthAlzheimer’s drug from Eli Lilly that can slow brain-robbing disease backed by FDA advisers
By Matthew Perrone and The Associated PressJune 11, 2024
Nestle CEO Mark Schneider
RetailNestlé’s new foods are getting Ozempified, with slashed portions priced specifically for those on weight-loss drugs
By Sasha RogelbergMay 21, 2024
Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk
RetailDenmark’s Novo Nordisk forecasts 27% sales surge but faces price pressure amid Eli Lilly competition
By Naomi Kresge and BloombergMay 2, 2024
HealthFDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer’s drug
By Tom Murphy, Matthew Perrone and The Associated PressMarch 8, 2024
tube of wegovy injections
LifestyleNovo Nordisk eclipses Tesla on positive trial results for a weight loss drug that may be more powerful than its own Wegovy 
By Prarthana PrakashMarch 8, 2024
WHO
HealthA billion people worldwide are obese and Ozempic and other weight-loss drugs aren’t a solution, WHO says
By Naomi Kresge, Angela Feliciano and BloombergMarch 1, 2024
HealthMinnesotans can buy insulin for just $35 a month over the next 5 years under a state settlement with Eli Lilly
By Steve Karnowski and The Associated PressFebruary 8, 2024
RetailNovo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
By Ryan HoggJanuary 31, 2024
1
  • 1
  • 2
  • 3
  • 4
  • 5
...7
Most Popular
Economy
Your grandparents are the reason the U.S. isn't in a recession right now. That won't last foreverAn image of a popular article
By Eleanor PringleMarch 1, 2026
Success
MacKenzie Scott's close relationship with Toni Morrison long before Amazon put her on the path give more than $1 billion to HBCUsAn image of a popular article
By Sasha RogelbergMarch 1, 2026
Personal Finance
Trump's universal 401(k) architect on why lower-income people distrust retirement accounts: 'they want to know what the catch is'An image of a popular article
By Jacqueline MunisFebruary 28, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
Fortune Secondary Logo
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.